Biotech's Covaxin shows good results in clinical trials: Research paper

Covaxin, a COVID-19 vaccine being

developed by Bharat Biotech, showed long-term antibody and T- cell (immune) memory responses three months after the shot in phase 1 volunteers and tolerable safety outcomes in Phase 2 study, the city-based company has said, suggesting the antibodies may persist for six to 12 months.

In phase 2, it also showed enhanced humoral and cell- mediated immune responses and the results were found in the safety and immunogenicity clinical trial of the vaccine candidate.

Memory T cells are antigen-specific T cells that remain over a long term after an infection has been eliminated.

Covaxin, being developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology, is now undergoing phase-3 trials.

In a double-blind, randomised, multi-centre phase 2 clinical trials, a total of 380 healthy children and adults were randomised and administered two vaccine formulations in as many doses (four weeks apart).

In a follow-up of the phase 1 trial, Covaxin (BBV152) produced high levels of neutralising antibodies that remained elevated in all participants three months (at day 104) after the second vaccination.

Based on these results, we hypothesise that BBV152 can generate antibodies that may persist for 6-12 months, Bharat Biotech said in a research paper on Covaxin.

The results from the phase 2 study show that both humoral and cell-mediated responses were observed. No neutralising antibody differences were observed between sexes and across age groups.

Covaxin was well tolerated in both dose groups with no serious adverse events, the research paper further said.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel